Most recently, Mr Shrewsbury served as chief medical officer and senior vice president of clinical development and regulatory affairs at Adamas Pharmaceuticals.
Prior to that, Mr Shrewsbury served as vice president of clinical and regulatory affairs and chief medical officer at Map Pharmaceuticals.
Leslie Hudson, president and CEO of Avi, said: “Stephen joins Avi at a time when his experience can favorably impact our pipeline and clinical programs. His extensive clinical and regulatory track record of success will serve us well as we advance AVI-4658 for the treatment of Duchenne muscular dystrophy and our other three clinical programs for the treatment of cardiovascular restenosis and Ebola and Marburg viral infections.”